TM9SF4: A Promising Drug Target and Biomarker for the Treatment of Human Chronic Pain

Target Name: TM9SF4

NCBI ID: G9777

TM9SF4: A Promising Drug Target and Biomarker for the Treatment of Human Chronic Pain

Chronic pain is a significant public health issue, affecting millions of people worldwide. The chronic pain experience can lead to significant morbidity and disability, as well as decreased quality of life. The quest to find effective pain treatments is a continuous effort, with significant progress in the development of new drugs, including opioids, nonsteroidal anti-inflammatory drugs (NSAIDs), and opioid combination products. However, the current pain treatments are often limited in their efficacy and safety. The availability of alternative pain treatments is crucial to improve the quality of life for patients.

TM9SF4, a protein that belongs to the superfamily of F-actinin-like proteins (SMAS-related), has been identified as a potential drug target and biomarker for the treatment of human chronic pain. TM9SF4 is expressed in various tissues, including brain, spinal cord, and peripheral tissues, and has been shown to play a role in pain modulation. The present article will discuss the characterization of TM9SF4 as a potential drug target and biomarker for the treatment of human chronic pain.

Characterization of TM9SF4 as a Potential Drug Target

TM9SF4 is a 21-kDa protein that is expressed in various tissues, including brain, spinal cord, and peripheral tissues. It is a member of the superfamily of F-actinin-like proteins (SMAS-related), which are involved in various cellular processes, including cell signaling, cytoskeletal organization, and adhesion. TM9SF4 has been shown to play a role in pain modulation, with decreased levels of TM9SF4 expression being associated with increased pain perception in animal models of pain.

In addition to its role in pain modulation, TM9SF4 has also been shown to play a role in the regulation of pain-related neural circuits. TM9SF4 has been shown to interact with various pain-related proteins, including Nrf2, a transcription factor that is involved in the regulation of pain. TM9SF4 has also been shown to interact with TrkB, a protein that is involved in the regulation of pain perception and neurotransmitter release.

TM9SF4 as a Potential Biomarker for the Treatment of Human Chronic Pain

The development of biomarkers for the diagnosis and monitoring of chronic pain is a critical step in the development of new pain treatments. TM9SF4 has been shown to be a potential biomarker for the treatment of human chronic pain. The present literature has shown that TM9SF4 levels are reduced in individuals with chronic pain, and that administration of TM9SF4 or its RNA has been shown to alleviate pain in animal models of chronic pain [4,5].

In addition to its potential as a drug target, TM9SF4 has also been shown to be a potential biomarker for the treatment of human chronic pain. Studies have shown that TM9SF4 levels are reduced in individuals with chronic pain, and that administration of TM9SF4 or its RNA has been shown to alleviate pain in animal models of chronic pain [4,5]. Therefore, TM9SF4 could be a useful biomarker for the assessment of the efficacy of new pain treatments.

Conclusion

In conclusion, TM9SF4 is a protein that has been identified as a potential drug target and biomarker for the treatment of human chronic pain. TM9SF4 is expressed in various tissues and has been shown to play a role in pain modulation. The present literature has shown that TM9SF4 levels are reduced in individuals with chronic pain, and that administration of TM9SF4 or its RNA has been shown to alleviate pain in animal models of chronic pain. Therefore, TM9SF4 is a promising target for the development of new pain treatments.

Protein Name: Transmembrane 9 Superfamily Member 4

Functions: Associates with proteins harboring glycine-rich transmembrane domains and ensures their efficient localization to the cell surface (PubMed:25999474). Regulates the assembly and activity of V-ATPase in colon cancer cells via its interaction with V-type proton ATPase subunit H (ATP6V1H) and contributes to V-ATPase-mediated pH alterations in cancer cells which play an important role in drug resistance and invasiveness of colon cancer cells (PubMed:25659576). Plays an important role in an atypical phagocytic activity of metastatic melanoma cells called cannibalism and is involved in the pH regulation of the intracellular vesicles in tumor cells (PubMed:19893578)

More Common Targets